Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2024 Feb 28;79(9):822–833. doi: 10.1136/thorax-2023-221071

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

PMC Copyright notice

Increased plasma IL-1β and C3d levels in AATD are decreased post AAT augmentation therapy. Levels of AAT (A), C3d (B) or IL-1β (C) were determined in plasma of healthy control subjects (HC, n=16), patients with AATD who are not on AAT therapy (n=28) and patients with AATD receiving weekly AAT augmentation therapy (AATD+AAT Aug, n=19). Significance was tested by one-way ANOVA, followed by Tukey’s posthoc multiple comparison test. (D) Positive correlation between C3d and IL-1β plasma levels (n=47; p<0.0001, two-tailed non-parametric Spearman correlation test). AAT, alpha-1 antitrypsin; AATD, alpha-1 antitrypsin deficiency; HC, healthy control.